Literature DB >> 32423769

Success of Weekly Adalimumab in Refractory Ocular Inflammatory Disease.

Jennifer Lee1, Anjum F Koreishi1, Katelyn B Zumpf2, Caroline L Minkus1, Debra A Goldstein3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32423769     DOI： 10.1016/j.ophtha.2020.04.009

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  6 in total

1.  Birdshot chorioretinopathy presenting in a teenager.

Authors:  Jennifer Lee; Wendy M Smith; Debra A Goldstein
Journal:  Am J Ophthalmol Case Rep       Date:  2020-07-03

Review 2.  New pharmacotherapy options for noninfectious posterior uveitis.

Authors:  Uwe Pleyer; Piergiorgio Neri; Christoph Deuter
Journal:  Int Ophthalmol       Date:  2021-02-25       Impact factor: 2.031

3.  Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis.

Authors:  Carlyn V Kouwenberg; Viera Koopman-Kalinina Ayuso; Joke H de Boer
Journal:  Acta Ophthalmol       Date:  2021-09-16       Impact factor: 3.988

4.  Weekly Adalimumab, an Effective Alternative for Refractory Uveitis in Children.

Authors:  Jordan E Roberts; Peter A Nigrovic; Mindy S Lo; Margaret H Chang
Journal:  J Clin Rheumatol       Date:  2022-01-01       Impact factor: 3.517

Review 5.  Old and New Challenges in Uveitis Associated with Behçet's Disease.

Authors:  Julie Gueudry; Mathilde Leclercq; David Saadoun; Bahram Bodaghi
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

Review 6.  Biotherapies in Uveitis.

Authors:  Mathilde Leclercq; Anne-Claire Desbois; Fanny Domont; Georgina Maalouf; Sara Touhami; Patrice Cacoub; Bahram Bodaghi; David Saadoun
Journal:  J Clin Med       Date:  2020-11-08       Impact factor: 4.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.